Country
Norway
Norway-based Targovax ASA has reported promising Phase 1 data for its oncolytic virus treatment ONCOS-102 in combination with pembrolizumab in patients with advanced, unresectable melanoma.
Full text available to subscribers only. Click here for information on subscribing to MedNous.